Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $150 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $150 price target.
July 01, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating on Alnylam Pharmaceuticals and maintained a $150 price target. This suggests that the analyst does not foresee significant short-term movement in the stock price.
The reiteration of a Neutral rating and the maintenance of the $150 price target indicate that the analyst does not expect significant changes in the stock's performance in the short term. This suggests a stable outlook for the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100